Sellas Life Sciences Shares Slide 10% After $150 Million Stock Sale Announced Following Trial-Driven Rally
Sellas Life Sciences (NASDAQ:SLS) shares fell 10% in after-hours trading after announcing a $150M stock sale. The company reported positive Phase 3 trial results for its cancer vaccine, GPS, showing a 41% reduction in death risk. Sellas plans to meet with the FDA for a potential 2027 BLA submission.
How this was made
The 30-second read
Why it matters
The new $150 million equity offering is the immediate catalyst, reframing the post-trial rally as a financing event and increasing dilution and execution uncertainty.
Market read
Traders should focus on offering pricing, completion probability, and how the market balances dilution against the accelerated BLA timeline.
What to watch
The deal is contingent on market conditions and includes an underwriter over-allotment option; final pricing and size could be less dilutive than feared if demand is strong.
Background
Sellas’ REGAL Phase 3 trial of galinpepimut-S (GPS) reported positive overall survival results, and the company is now pursuing an accelerated filing path with FDA discussions.
Ticker impact
Sellas announced a $150 million underwritten public offering of common stock, triggering an after-hours ~10% slide and dilution risk.
Likely further near-term pressure as investors price dilution and uncertainty around offering completion and final terms.
The article ties the after-hours drop directly to the announced $150M offering, with an additional 30-day over-allotment option and contingent completion language.
Market effects
Reinforces the common small-cap biotech pattern of equity issuance immediately after positive pivotal trial data, which can raise sector-wide dilution expectations.
Primarily impacts US small-cap biotech sentiment and liquidity conditions for NASDAQ-listed clinical-stage issuers.
Limited direct global spillover; could influence investor appetite for WT1 immunotherapy and AML vaccine programs internationally.
Counterpoint
The offering may be a funding bridge to accelerate FDA discussions and a first-half 2027 BLA, which could reduce future financing risk if the accelerated path is credible.
Key entities
- companySellas Life Sciences Group Inc
NASDAQ-listed biotech whose shares fell after announcing a $150 million underwritten public offering following positive REGAL trial topline data.
- clinical_trialREGAL trial
Phase 3 registrational study of GPS in AML second or later complete remission patients, meeting the primary overall survival endpoint.
- regulatorU.S. Food and Drug Administration (FDA)
Sellas plans to meet to discuss an accelerated filing path and prepare a BLA for GPS in the first half of 2027.

